Alice (688578.SH) issued an advance increase. Net profit due to mother for the half-year is expected to be 1.54 billion yuan, an increase of 46.49% over the previous year

According to Zhitong Finance App News, Alice (688578.SH) announced that the company expects to achieve net profit attributable to owners of the parent company for the first half year of 2026 of 1.54 billion yuan, an increase of 46.49% over the previous year.

During the reporting period, the company actively exploited the synergy of commercial products, formed multi-level development momentum, and gave full play to the company's platform advantages in the field of oncology. With the support and coverage of the national health insurance policy, with outstanding differentiated clinical advantages, revenue related to vometinib mesylate tablets, golecide citrate tablets, and the commercially promoted product Platinib capsule products continued to grow, driving the company's business performance to continue to rise.